Virax Biolabs Group Limited · NASDAQ:VRAX
Virax Biolabs — Investor Presentation (April 2026)
16 slides from Virax Biolabs's investor presentation, April 2026
Slide 1: Investor Presentation Q2 2026
Investor Presentation Q2 2026 NASDAQ : VRAX
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events
Slide 3: Next-generation diagnostics for chronic inflammation and immune dysfunction
Next-generation diagnostics for chronic inflammation and immune dysfunction Our lead product, ViraxImmune is designed to be one of the first assays to objectively assess immune dysfunction in post-acute infection syndromes (PAIS), where there are currently no approved objective diagnostic tests in m
Slide 4: PAIS conditions: A large, under-served diagnostic category
PAIS conditions: A large, under-served diagnostic category Millions of people each year are Long diagnosed with PAIS conditions including ME/CFS, Long COVID, and COVID post-treatment Lyme disease (PTLD) $6.5B Expert estimates suggest an economic burden in excess of $25bn in the US alone1-3 ME / CFS
Slide 5: PAIS patient journey: Reducing diagnostic costs through objective testing
PAIS patient journey: Reducing diagnostic costs through objective testing Currently, clinicians speculate PAIS based on the exclusion of other diagnoses. A validated, objective immune dysfunction diagnostic, such as ViraxImmune , could help shorten time-to-diagnosis and reduce overall diagnostic bur
Slide 6: PAIS and immune dysfunction: Evolving treatment landscapes
PAIS and immune dysfunction: Evolving treatment landscapes EXAMPLES OF TREATMENT AREAS USED IN LONG COVID AND ME/CFS CARE Long COVID and ME/CFS currently lack FDA-approved Autonomic / Immune / treatments, with real-world care spanning a broad range cardiovascular inflammatory of symptom-targeted int
Slide 7: ViraxImmune: Planned US market entry via Laboratory Developed Tests
ViraxImmune : Planned US market entry via Laboratory Developed Tests Sample collection Planned path to market: 1. Initial LDT launch PAIS (Post-Acute Infection Syndrome) is the lead indication Biobank / processing Additional indications to be advanced selectively as clinical data matures 2. Subs
Slide 8: ViraxImmune: Coding roadmap
ViraxImmune : Coding roadmap Our market access strategy targets the established ‘Gapfill’ CMS reimbursement pathway to establish payment when no comparable test exists, facilitating the commercial availability and long-term valuation goals for ViraxImmune Phase Coding Mechanism Market Access Objecti
Slide 9: Future reimbursement expectations (PLA code)
ViraxImmune : Future reimbursement expectations (PLA code) Following initial US LDT billing under CPT 86849, planned transition to a Proprietary (PLA) identifier would support the next stage of reimbursement development, followed over time by a permanent Category I framework. Future reimbursement ex
Slide 10: Illustrative US LDT service revenue framework
ViraxImmune : Illustrative US LDT service revenue framework According to recent estimates, up to 21M adults in the US are currently living with PAIS conditions. Each year in the US, around 2.5M people are newly diagnosed with PAIS conditions. US population 342M Primary Launch Case Based on 1%-2% of
Slide 11: Clinical Studies Supporting Commercialisation
ViraxImmune : Clinical Studies Supporting Commercialisation VRX-002 VRX-003 Exploring the link between Assessing the analytical Focused on establishing immune cell dysfunction performance of and persistent post-infection ViraxImmuneTM products. the clinical evidence symptoms. required for UK IVD and
Slide 12: Key milestones and US launch timeline
ViraxImmune : Key milestones and US launch timeline 2025 2026 2027 2028 Foundation Validation LDT Launch IVD Launch ✓ FDA Q-Sub (Pre-Submission) meeting completed; PAIS clinical & analytical performance data US central laboratory establishment FDA IVD clearance feedback received to inform read-out (
Slide 13: Virax Biolabs: Financial and investment highlights
Virax Biolabs: Financial and investment highlights Market Cap at April 10, 2026 $2.6M Unaudited Cash at March 31, 2026 $6.4M PIPE transaction December 3, 2025 $5.0 M Following its recent financing and based on its unaudited cash position No Options outstanding at March 31, 2026 437,250 at $6.08 at M
Slide 14: Partner with us as we bridge the diagnostic gap
Virax Biolabs: Next-generation diagnostics for chronic inflammation and immune dysfunction. Partner with us as we bridge the diagnostic gap for millions of under-served patients. NASDA Q : VRA X 14
Slide 15: www.viraxbiolabs.com
virax Y biolabs www.viraxbiolabs.com
Slide 16: Appendix 1: References
Appendix 1: References Slide 4: 1. Bartsch SM, et al. The Current and Future Burden of Long COVID in the United States (U.S.) (2025) J Infect Dis, 231(6):1581-1590 2. “What Is ME/CFS?” CDC, 10 May 2024, www.cdc.gov/me-cfs/about/index.html. 3. “Economic Burden of Lyme Disease Could Be Nearly $1 Billi
Virax Biolabs Group — Investor Presentation (April 2026) on 6ix